ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 125 for:    chronic fatigue syndrome

Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03029377
Recruitment Status : Completed
First Posted : January 24, 2017
Last Update Posted : April 26, 2018
Sponsor:
Information provided by (Responsible Party):
Gordon Bernard, Vanderbilt University Medical Center

Brief Summary:
The objective of this study is to measure sympathetic nervous system function and stress responses in patients with clinically documented and self-reported chronic fatigue that is worsened by stress, compared to healthy controls. Baseline norepinephrine (NE) levels and stress-induced NE levels in patients who fulfill criteria for Chronic Fatigue Syndrome (CFS) and who self-identify with stress induced worsening fatigue, will be compared to data from normal individuals pre and post-stress.

Condition or disease Intervention/treatment Phase
Chronic Fatigue Syndrome Other: Posture Study, Autonomic Function Tests, and a Stress Test Not Applicable

Detailed Description:

Symptoms of Chronic Fatigue Syndrome (CFS) are critically important to study as patients report that these symptoms are often profoundly debilitating and an impediment to effective daily functioning as well as effective vocational and social functioning, while also contributing to a significantly increased risk of psychiatric illness and diminished quality of life. Previous Phenome-Wide Association (PheWAS) studies revealed a link between a norepinephrine transporter (NET) genetic variant and CFS. Based on the potential function of the variant and published literature, elevated norepinephrine (NE) levels may underlie at least some cluster of fatigue symptoms. Some patients may experience chronic fatigue that is due to an excess of circulating NE, and fatigue symptoms are reported by our patient population to be commonly exacerbated by stress. This study will test the hypothesis that in a subset of people with severely debilitating fatigue of long duration (>6 months) that is worsened by stress identified through the Vanderbilt electronic health record phenotyping study, have chronic over-release of the hormone NE into the bloodstream/periphery over time that results in an overload of NE. This overload of NE causes a compensatory but deleterious effect on the brain and nervous system, including sympathetic effects and dysregulated physiologic response to stress. Thus, while numerous currently approved therapies that target NET inhibit the transporter, a drug with the opposite mechanism of action, a NET activator that would decrease circulating NE, may have efficacy in treating underlying pathophysiology of chronic fatigue.

Baseline NE levels and stress-induced NE levels in patients who fulfill criteria for CFS and who self-identify with stress induced worsening fatigue, will be compared to data from normal individuals pre and post-stress. After all inclusion criteria has been confirmed, an IV will be placed for blood collection, a continuous electrocardiographic trace and blood pressure cuff will be placed on the subject's arm and finger. Subjects will undergo a posture study, autonomic reflex testing, and Stroop stress testing each followed by blood specimen collection. An optional blood draw for DNA analysis will occur after patients have been provided lunch. Questionnaires will be completed after study procedures and patients have been provided lunch. Study blood collection will total up to 28 milliliters (mL): 5 mL for cytokines, 20 mL for catecholamines, and optional 3 mL for DNA.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
Actual Study Start Date : January 2017
Actual Primary Completion Date : February 23, 2018
Actual Study Completion Date : February 23, 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Chronic Fatigue Patients
Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
Other: Posture Study, Autonomic Function Tests, and a Stress Test
Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
Active Comparator: Healthy Controls
Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
Other: Posture Study, Autonomic Function Tests, and a Stress Test
Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.



Primary Outcome Measures :
  1. dihydroxyphenylglycol (DHPG)/norepinephrine (NE) Ratio (post stress) [ Time Frame: Change from Baseline to post stress test (approximately 100 minutes post-baseline blood collection) ]
    Change in DHPG/NE Ratio from Baseline to post stress compared across arms


Secondary Outcome Measures :
  1. DHPG/NE Ratio (post Autonomic Function test) [ Time Frame: Change from Baseline to post Autonomic Function test (approximately 30 minutes post-baseline blood collection) ]
    Change in DHPG/NE Ratio from Baseline to post Autonomic Function test compared across arms

  2. DHPG/NE Ratio (post Standing position) [ Time Frame: Change from Baseline to post Standing position (approximately 40 minutes post-baseline blood collection) ]
    Change in DHPG/NE Ratio from Baseline to post Standing position compared across arms

  3. DHPG/NE Ratio (post Sitting position) [ Time Frame: Change from Baseline to post Sitting position (approximately 70 minutes post-baseline blood collection) ]
    Change in DHPG/NE Ratio from Baseline to post Sitting position compared across arms

  4. Absolute DHPG and NE Levels (post stress) [ Time Frame: Change from Baseline to post stress test (approximately 100 minutes post-baseline blood collection) ]
    Change in absolute DHPG and NE Levels from Baseline to post stress compared across arms

  5. Absolute DHPG and NE Levels (post Autonomic Function test) [ Time Frame: Change from Baseline to post Autonomic Function test (approximately 30 minutes post-baseline blood collection) ]
    Change in DHPG and NE levels from Baseline to post Autonomic Function test compared

  6. Absolute DHPG and NE Levels (post Standing position) [ Time Frame: Change from Baseline to post Standing position (approximately 40 minutes post-baseline blood collection) ]
    Change in absolute DHPG and NE Levels from Baseline to post Standing position compared across arms

  7. Absolute DHPG and NE Levels (post Sitting position) [ Time Frame: Change from Baseline to post Sitting position (approximately 70 minutes post-baseline blood collection) ]
    Change in DHPG and NE levels from Baseline to post Sitting position compared across arms

  8. Fatigue as assessed by Multidimensional Assessment of Fatigue Scale (MAF) [ Time Frame: End of Study Visit (approximately 140 minutes post-baseline blood collection) ]
    Mean values +/- standard deviation (SD) compared across arms

  9. Mood as assessed by Hospital Anxiety and Depression Scale (HADS) [ Time Frame: End of Study Visit (approximately 140 minutes post-baseline blood collection) ]
    Mean values +/- SD compared across arms

  10. Quality of Life as assessed by 36-Item Short Form Survey Instrument (SF-36) [ Time Frame: End of Study Visit (approximately 140 minutes post-baseline blood collection) ]
    Mean values +/- SD compared across arms

  11. Stress as assessed by Stress Overload Scale [ Time Frame: Beginning of Study Visit (Approximately 15 minutes pre-baseline blood collection) ]
    Mean values +/- SD compared across arms

  12. Cytokines [ Time Frame: At baseline (approximately 30 minutes after supine position start) ]
    Compared across arms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Chronic Fatigue Participants:

Inclusion Criteria:

  • Confirmed chronic fatigue with severity >50 on a scale of 1 to 100 that is not improving over time
  • Meet The Centers for Disease Control and Prevention (CDC) diagnostic criteria of CFS (self-reported persistent or relapsing fatigue lasting 6 or more consecutive months)

Exclusion Criteria:

  • Male and female subjects <18 or >60 years
  • Obesity, defined as a BMI of 30 or more
  • Presence of other medical or psychiatric conditions known to cause fatigue (alcohol/drug abuse, anorexia nervosa, bipolar disorder, bulimia nervosa, dementia, major depression, psychotic/delusional disorders, schizophrenia)
  • Presence of sleep disorder/disruption known to cause fatigue (sleep apnea, narcolepsy)
  • Cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing defined as significant by investigator (including but not limited to chronic hepatitis, chronic kidney disease, cirrhosis, emphysema, heart failure, HIV, lupus, multiple sclerosis, myasthenia gravis, rheumatoid arthritis)
  • History of hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
  • Patients taking medications that can affect autonomic function or plasma catecholamines (vasoactive drugs), stimulants, and/or are sedatives
  • Other factors which in the opinion of the investigator could potentially impact the study outcomes (e.g., underlying disease, medications, history)* or prevent the participant from completing the protocol (poor compliance or unpredictable schedule)
  • Inability to stand unassisted for 10 minutes
  • Patients who are bedridden or chair-ridden
  • Patients who are colorblind
  • Inability or refusal to give informed consent for any reason including a diagnosis of dementia or cognitive impairment
  • Patients who are pregnant or breastfeeding

Healthy Control Participants:

  • Participant with no significant reported conditions or medications.

Exclusion Criteria:

  • Male and female subjects <18 or >60 years
  • Obesity, defined as a BMI of 30 or more
  • Presence of any serious or chronic disease, or prescription medication as deemed by investigator including hypertension as defined by supine resting BP >145/95 mmHg off medications or needing antihypertensive medication
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
  • Inability to stand unassisted for 10 minutes
  • Patients who are bedridden or chair-ridden
  • Patients who are colorblind
  • Inability or refusal to give informed consent for any reason including a diagnosis of dementia or cognitive impairment
  • Patients who are pregnant or breastfeeding
  • Stress Overload Score above 66

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03029377


Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Vanderbilt University Medical Center
Investigators
Principal Investigator: Gordon Bernard, MD Vanderbilt University Medical Center

Additional Information:
Publications:
Responsible Party: Gordon Bernard, Executive Vice President for Research, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT03029377     History of Changes
Other Study ID Numbers: 161423
First Posted: January 24, 2017    Key Record Dates
Last Update Posted: April 26, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Gordon Bernard, Vanderbilt University Medical Center:
CFS
Stress
Norepinephrine Transporter (NET)
Norepinephrine (NE)
Healthy Controls
Fatigue

Additional relevant MeSH terms:
Syndrome
Fatigue
Fatigue Syndrome, Chronic
Disease
Pathologic Processes
Signs and Symptoms
Virus Diseases
Muscular Diseases
Musculoskeletal Diseases
Encephalomyelitis
Central Nervous System Diseases
Nervous System Diseases
Neuromuscular Diseases
Norepinephrine
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents